Search research articles
Contact Us
Filters
Showing results (31-40 of 46) with videos related to
Page
of 5
Sort By:
Cancer Treatment Reports
|
August 1, 1977
High-dose methotrexate with citrovorum factor rescue: predictive value of serum methotrexate concentrations and corrective measures to avert toxicity
A Nirenberg, C Mosende, B M Mehta, et al.
Nuclear Medicine and Biology
|
March 30, 1999
Measurement of P-glycoprotein expression in human neuroblastoma xenografts using in vitro quantitative autoradiography
R Fonti, A Levchenko, B M Mehta, et al.
Neurology
|
September 1, 1979
Enhancement of CNS penetration of methotrexate by hyperosmolar intracarotid mannitol or carcinomatous meningitis
H Hasegawa, J C Allen, B M Mehta, et al.
National Cancer Institute Monograph
|
April 1, 1981
Prognostic factors in the response of primary osteogenic sarcoma to preoperative chemotherapy (high-dose methotrexate with citrovorum factor)
H Juergens, C Kosloff, A Nirenberg, et al.
Scientific Reports
|
August 13, 2024
Value addition to dietetic frozen yoghurt through use of fruit peel solids
Shaikh Adil, A H Jana, B M Mehta, et al.
Cancer Investigation
|
January 1, 1987
Systemic absorption of a leucovorin mouth wash: a pharmacologic study
J J Fiore, N E Kemeny, B M Mehta, et al.
Cancer Treatment Reports
|
March 1, 1978
Serum distribution of citrovorum factor and 5-methyltetrahydrofolate following oral and im administration of calcium leucovorin in normal adults
B M Mehta, A L Gisolfi, D J Hutchison, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 1, 1992
In-vivo identification of tumor multidrug resistance with 3H-colchicine [corrected]
B M Mehta, E Rosa, J D Fissekis, et al.
Basic Life Sciences
|
January 1, 1991
Tumor heterogeneity and intrinsically chemoresistant subpopulations in freshly resected human malignant gliomas
J R Shapiro, B M Mehta, S A Ebrahim, et al.
National Cancer Institute Monograph
|
April 1, 1981
Osteogenic sarcoma: eight-percent, three-year, disease-free survival with combination chemotherapy (T-7)
G Rosen, A Nirenberg, B Caparros, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 46) with videos related to
Sort By:
Page
of 5
Cancer Treatment Reports
|
August 1, 1977
High-dose methotrexate with citrovorum factor rescue: predictive value of serum methotrexate concentrations and corrective measures to avert toxicity
A Nirenberg, C Mosende, B M Mehta, et al.
Nuclear Medicine and Biology
|
March 30, 1999
Measurement of P-glycoprotein expression in human neuroblastoma xenografts using in vitro quantitative autoradiography
R Fonti, A Levchenko, B M Mehta, et al.
Neurology
|
September 1, 1979
Enhancement of CNS penetration of methotrexate by hyperosmolar intracarotid mannitol or carcinomatous meningitis
H Hasegawa, J C Allen, B M Mehta, et al.
National Cancer Institute Monograph
|
April 1, 1981
Prognostic factors in the response of primary osteogenic sarcoma to preoperative chemotherapy (high-dose methotrexate with citrovorum factor)
H Juergens, C Kosloff, A Nirenberg, et al.
Scientific Reports
|
August 13, 2024
Value addition to dietetic frozen yoghurt through use of fruit peel solids
Shaikh Adil, A H Jana, B M Mehta, et al.
Cancer Investigation
|
January 1, 1987
Systemic absorption of a leucovorin mouth wash: a pharmacologic study
J J Fiore, N E Kemeny, B M Mehta, et al.
Cancer Treatment Reports
|
March 1, 1978
Serum distribution of citrovorum factor and 5-methyltetrahydrofolate following oral and im administration of calcium leucovorin in normal adults
B M Mehta, A L Gisolfi, D J Hutchison, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 1, 1992
In-vivo identification of tumor multidrug resistance with 3H-colchicine [corrected]
B M Mehta, E Rosa, J D Fissekis, et al.
Basic Life Sciences
|
January 1, 1991
Tumor heterogeneity and intrinsically chemoresistant subpopulations in freshly resected human malignant gliomas
J R Shapiro, B M Mehta, S A Ebrahim, et al.
National Cancer Institute Monograph
|
April 1, 1981
Osteogenic sarcoma: eight-percent, three-year, disease-free survival with combination chemotherapy (T-7)
G Rosen, A Nirenberg, B Caparros, et al.
Page
of 5